OncRef

Clinical Trial: NCT04846634

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

Status:

NOT YET RECRUITING

Phase:

Phase 2

Lead Sponsor:Tianjin Medical University Cancer Institute and Hospital
Information Provided By:Tianjin Medical University Cancer Institute and Hospital
Last Update Posted:2021-04-15

Study Overview

Brief Summary

This is a multicenter, randomized, open label, phase II study.

Official Title

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

Conditions

Resectable Locally Advanced Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel
  • Drug: Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel
  • Drug: Penpulimab+Anlotinib

Other Study ID Numbers

  • ALTER-L043

Start Date (Estimated)

2021-08

Primary Completion Date (Estimated)

2023-03

Study Completion Date (Estimated)

2028-02

Enrollment (Estimated)

90

Study Type

Interventional

Phase

Phase 2